Skip to content
Clinical Trials – home
Therapeutic area

Psychiatric disorders

  • 546 clinical trials
  • 244 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Orforglipron for stress urinary incontinence in women with obesity or overweight

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Narcolepsy

Recruiting

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pitolisant
  • Sponsor:Harmony Biosciences Management Inc.

Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Agitation+1

Recruiting

A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Deramciclane
  • Sponsor:Exciva GmbH

A study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Insomnia

Recruiting

Study of tasimelteon compared to placebo for treating insomnia in children

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tasimelteon
  • Sponsor:Vanda Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.